Insider Selling: Standard BioTools Inc. (NASDAQ:LAB) SVP Sells 13,217 Shares of Stock

Standard BioTools Inc. (NASDAQ:LAB - Get Free Report) SVP Sean Mackay sold 13,217 shares of the business's stock in a transaction on Friday, May 23rd. The shares were sold at an average price of $0.94, for a total transaction of $12,423.98. Following the completion of the sale, the senior vice president now directly owns 843,076 shares of the company's stock, valued at approximately $792,491.44. This trade represents a 1.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Sean Mackay also recently made the following trade(s):

• On Thursday, May 22nd, Sean Mackay sold 12,536 shares of Standard BioTools stock. The shares were sold at an average price of $1.00, for a total transaction of $12,536.00.
• On Wednesday, May 21st, Sean Mackay sold 12,838 shares of Standard BioTools stock. The shares were sold at an average price of $1.03, for a total transaction of $13,223.14.

Standard BioTools Price Performance

Shares of NASDAQ:LAB traded up $0.04 on Monday, reaching $1.05. The company's stock had a trading volume of 1,566,323 shares, compared to its average volume of 2,125,157. The stock's 50-day moving average is $1.10 and its two-hundred day moving average is $1.41. Standard BioTools Inc. has a 52-week low of $0.92 and a 52-week high of $2.60. The stock has a market capitalization of $398.81 million, a P/E ratio of -1.48 and a beta of 1.80.

Institutional Investors Weigh In On Standard BioTools

A number of institutional investors and hedge funds have recently made changes to their positions in LAB. Long Focus Capital Management LLC purchased a new stake in shares of Standard BioTools in the first quarter valued at about $7,236,000. Mirabella Financial Services LLP purchased a new stake in shares of Standard BioTools in the fourth quarter valued at about $5,478,000. Pacific Capital Partners Ltd purchased a new stake in shares of Standard BioTools in the first quarter valued at about $1,701,000. Royce & Associates LP raised its holdings in shares of Standard BioTools by 136.8% in the fourth quarter. Royce & Associates LP now owns 1,455,503 shares of the company's stock valued at $2,547,000 after buying an additional 840,951 shares during the last quarter. Finally, Nuveen LLC purchased a new stake in shares of Standard BioTools in the first quarter valued at about $862,000. 53.74% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, KeyCorp cut shares of Standard BioTools from an "overweight" rating to a "sector weight" rating in a research report on Thursday, February 27th.

About Standard BioTools

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.